Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

534 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty.
Akkerhuis KM, van Den Brand MJ, van Der Zwaan C, Peels HO, Suryapranata H, van Der Wieken LR, Stibbe J, Hoffmann J, Baardman T, Deckers JW, Simoons ML. Akkerhuis KM, et al. Among authors: simoons ml. Heart. 2001 Apr;85(4):444-50. doi: 10.1136/heart.85.4.444. Heart. 2001. PMID: 11250974 Free PMC article. Clinical Trial.
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
Akkerhuis KM, Deckers JW, Boersma E, Harrington RA, Stepinska J, Mahaffey KW, Wilcox RG, Lincoff AM, Keltai M, Topol EJ, Califf RM, Simoons ML. Akkerhuis KM, et al. Among authors: simoons ml. Eur Heart J. 2000 Mar;21(5):371-81. doi: 10.1053/euhj.1999.1743. Eur Heart J. 2000. PMID: 10666351 Clinical Trial.
Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
Akkerhuis KM, Maas AC, Klootwijk PA, Krucoff MW, Meij S, Califf RM, Simoons ML. Akkerhuis KM, et al. Among authors: simoons ml. J Electrocardiol. 2000 Apr;33(2):127-36. doi: 10.1016/s0022-0736(00)80069-2. J Electrocardiol. 2000. PMID: 10819406 Clinical Trial.
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML; Fibrinogen Receptor Occupancy Study (FROST) Investigators. Akkerhuis KM, et al. Among authors: simoons ml. Eur Heart J. 2000 Dec;21(24):2042-55. doi: 10.1053/euhj.2000.2309. Eur Heart J. 2000. PMID: 11102255 Clinical Trial.
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
Ronner E, Boersma E, Akkerhuis KM, Harrington RA, Lincoff AM, Deckers JW, Karsch K, Kleiman NS, Vahanian A, Topol EJ, Califf RM, Simoons ML. Ronner E, et al. Among authors: simoons ml. Eur Heart J. 2002 Feb;23(3):239-46. doi: 10.1053/euhj.2001.2736. Eur Heart J. 2002. PMID: 11792139 Clinical Trial.
534 results